Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00725686 · ClinicalTrials.gov registry record · Phase 1

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

A Phase 1 study, sponsored by Quark Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target

NCT00725686: Completed Phase 1 study, sponsored by Quark Pharmaceuticals.

NCT00725686 is a Phase 1 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00725686, a Phase 1 study, has completed, sponsored by Quark Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

Interventions

  • DRUG PF-04523655

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2007-02
Est. Completion 2010-11
Phase Phase 1
Quark Pharmaceuticals

14 total trials

What the finished NCT00725686 record still lists

NCT00725686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).

The record links to 0 conditions, and to 1 intervention - of which PF-04523655 is the first listed.

NCT00725686 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00725686 about?

NCT00725686 is a clinical study titled "Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)". The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

What is the current status of trial NCT00725686?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2007-02. Estimated completion is 2010-11.

What interventions are being tested in trial NCT00725686?

The interventions under investigation include: PF-04523655 (DRUG).

Who is sponsoring clinical trial NCT00725686?

This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00725686's enrollment target sits among peer trials

54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00725686, the US trial registry maintained by the National Library of Medicine. NCT00725686 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.